Abstract: The present invention aims to produce a safe and reliable medical composition, which efficiently boosts nonspecific immunity of antigen-presenting cells and thereby promotes an antitumor activity. To produce the medical composition, antigen-presenting cells such as dendritic cells are exposed to an activating reagent containing baculoviruses. Then, the antigen-presenting cells are separated from the activating reagent. The antigen-presenting cells are optionally cultured after the separation. Furthermore, an absence of the baculoviruses in the composition are optionally checked. The medical composition produced by the present invention is expected to have an outstanding therapeutic effect.

Abstract: An RNAi reagent and a medicine that have no adverse effects such as interferon and/or cytotoxicity induction are provided. An shRNA used for sequence-specific RNA interference without interferon and/or cytotoxicity induction and a medicine and a reagent containing the shRNA are provided, such shRNA comprising a sense strand comprising a sequence homologous to a target sequence of the target mRNA and an antisense strand comprising a sequence complementary to the sequence of the sense strand and having an overhang comprising one or a plurality of G(s) at the 5? end of the sense strand.

Abstract: A novel antisense oligonucleotide that targets at DIS (Dimerization Initiation Site) region of HIV-1; and an anti-HIV agent (HIV curative and/or preventive agent) comprising the same. This anti-HIV agent realizes effective treatment and/or prevention for HIV infection.

Abstract: Antisense oligonucleotide sequences which enable the measurement of the distribution and structure of antisense oligonucleotide drugs in the body, with lapse of time, and a method of detecting these sequences are provided. The antisense chains have a natural or non-natural nucleotide or peptide nucleic acid as a structural unit in which carbon atoms and nitrogen atoms are substituted by 13C and 15N, respectively, and the antisense chains can be detected by nuclear magnetic resonance spectroscopy (NMR) such as 15N—1H or 13C—1H hetero nuclear multiple quantum coherence spectroscopy.

Abstract: Antisense oligonucleotide sequences which enable the measurement of the distribution and structure of antisense oligonucleotide drugs in the body, with lapse of time, and a method of detecting these sequences are provided. The antisense chains have a natural or non-natural nucleotide or peptide nucleic acid as a structural unit in which carbon atoms and nitrogen atoms are substituted by 13C and 15N, respectively, and the antisense chains can be detected by nuclear magnetic resonance spectroscopy (NMR) such as 15N—1H or 13C—1H hereto nuclear multiple quantum coherence spectroscopy.

Abstract: Each of slave recorders includes a rotary drum, heads mounted on the rotary drum at positions spaced from a phase reference position on the rotary drum by different angular intervals respectively, and an arrangement for selecting at least one from the heads as an active head in accordance with a designated recording mode. Non-delayed stream data are delayed by a delay time interval to form delayed stream data. A distributor operates for distributing the delayed stream data to the slave recorders. Each of the slave recorders records the delayed stream data on a slave recording medium by the active head. The delay time interval corresponds to the angular interval between the phase reference position and the position of the active head.

Abstract: It is intended to provide virus vector vaccine preparations containing as the main component a virus vector with the use of a virus showing no pathogenicity on humans and being free from a risk of the re-acquisition of pathogenicity. Namely, vaccine preparations containing as the main component a baculovirus having a gene encoding an antigen integrated thereinto are provided.

Abstract: Antisense oligonucleotide sequences which enable the measurement of the distribution and structure of antisense oligonucleotide drugs in the body, with lapse of time, and a method of detecting these sequences are provided. The antisense chains have a natural or non-natural nucleotide or peptide nucleic acid as a structure unit in which carbon atoms and nitrogen atoms are substituted by 13C and 15N, respectively, and the antisense chains can be detected by nuclear magnet resonance spectrometry (NMR) such as 5N—1H or 13C—1H heteronuclide multiple quantum coherence spectrometry.

Abstract: A pharmaceutical composition for treating or preventing influenza comprising an oligonucleotide containing a base sequence complementary to a base sequence of a target region containing a translational initiation codon AUG of a PB2 gene or a PA gene, a liposome stable in blood, and a pharmaceutically acceptable carrier or dilute is disclosed. The pharmaceutical composition for treating or preventing influenza can be used in an effective treatment of or prevention of an infection by influenza viruses.

Abstract: A pharmaceutical composition comprising a capped oligonucleotide capable of binding to a PB2 protein of an influenza virus RNA polymerase, and a pharmaceutically acceptable carrier or dilute, said capped oligonucleotide having a structure of the formula (I): m7GpppXpY  (I) wherein ppp is a triphosphate bridge, p is a monophosphate bridge, m7G is 7-methylguanosine group binding at 5′ end thereof to said ppp, X is a 2′-O-methyl guanosine group or guanosine group, said 2′-O-methyl guanosine group or guanosine group binds at a 5′ end thereof to said ppp, and at a 3′ end thereof to said p, and Y is an oligoribonucleotide moiety binding at 5′ end thereof to said p, and having 5 to 11 bases is disclosed. The pharmaceutical composition can inhibit a protein expression of an influenza virus.

Abstract: Each of slave recorders includes a rotary drum, heads mounted on the rotary drum at positions spaced from a phase reference position on the rotary drum by different angular intervals respectively, and an arrangement for selecting at least one from the heads as an active head in accordance with a designated recording mode. Non-delayed stream data are delayed by a delay time interval to form delayed stream data. A distributor operates for distributing the delayed stream data to the slave recorders. Each of the slave recorders records the delayed stream data on a slave recording medium by the active head. The delay time interval corresponds to the angular interval between the phase reference position and the position of the active head.

Abstract: The invention provides novel phosphites represented by the general formula (I) and nucleoside-3'-phosphite derivatives represented by the general formula (III).(RO).sub.3 P (I)wherein R is, for example, a fluoroalkyl group or a substituted phenyl group. ##STR1## wherein R is the same as in (I), R" is a protecting group such as dimethoxytrityl group, and B represents a base, e.g. thymine.A phosphite (I) is prepared by reacting an alcohol ROH with PCl.sub.3 in the presence of a tertiary amine, and a nucleoside-3'-phosphite (III) is prepared by reacting a phosphite (I) with a nucleoside in a solvent in the presence of a tertiary amine. Phosphites (I) are very stable. Using a nucleoside-3'-phosphite (III) an oligonucleotide can be synthesized on a solid support by a simplified process.

Abstract: Process for the production of 4',5'-unsaturated nucleosides via a novel compound, 5'-Se-(2- or 4-nitrophenyl)-selenonucleoside, is disclosed, said selenonucleoside being represented by the formula ##STR1## wherein R is a hydrogen atom or a hydroxyl group, A is 2- or 4-nitrophenyl group and B is a base.